Literature DB >> 25016654

Dynamic contrast enhanced fluorescent molecular imaging of vascular disruption induced by combretastatin-A4P in tumor xenografts.

Li Liu, Xing Su, Ralph P Mason.   

Abstract

Dynamic contrast enhanced (DyCE) fluorescence imaging was recently demonstrated for identifying the organs in mice based on principal component analysis (PCA) of contrast kinetics following infusion of indocyanine green (ICG). It occurred to us that this approach could be used to evaluate acute effects of vascular disrupting agents (VDAs), since these cause massive vascular shutdown. As proof of principle, we have examined the action of combretastatin-A4P (CA4P) on MCF7 human breast tumors growing in nude mice. Tumors were implanted in the thigh and allowed to grow to about 7 mm diameter. Indocyanine green (ICG; 50 microl 260 microM) was administered as a bolus by tail vein injection to anesthetized mice. The fluorescence time course was acquired over 200 s using a sensitive charge-coupled device (CCD) camera system. CA4P was then administered IP (120 mg/kg in 100 microl saline) and DyCE repeated following administration of fresh ICG two and 24 hours later. At 2 hours the developed fluorescence intensity was much reduced in the tumors indicating vascular impairment, which was confirmed histologically. After 24 hours there was considerable recovery. Good reproducibility was found for control mice and normal organs. We believe the method shows promise for developing VDAs by evaluating and optimizing therapeutic drug doses and combinations.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25016654      PMCID: PMC5540362          DOI: 10.1166/jbn.2014.1949

Source DB:  PubMed          Journal:  J Biomed Nanotechnol        ISSN: 1550-7033            Impact factor:   4.099


  30 in total

1.  Synthesis of a 2-aryl-3-aroyl indole salt (OXi8007) resembling combretastatin A-4 with application as a vascular disrupting agent.

Authors:  Mallinath B Hadimani; Matthew T Macdonough; Anjan Ghatak; Tracy E Strecker; Ramona Lopez; Madhavi Sriram; Benson L Nguyen; John J Hall; Raymond J Kessler; Anupama R Shirali; Li Liu; Charles M Garner; George R Pettit; Ernest Hamel; David J Chaplin; Ralph P Mason; Mary Lynn Trawick; Kevin G Pinney
Journal:  J Nat Prod       Date:  2013-09-09       Impact factor: 4.050

2.  Dynamic contrast-enhanced optical imaging of in vivo organ function.

Authors:  Cyrus B Amoozegar; Tracy Wang; Matthew B Bouchard; Addason F H McCaslin; William S Blaner; Richard M Levenson; Elizabeth M C Hillman
Journal:  J Biomed Opt       Date:  2012-09       Impact factor: 3.170

3.  In vivo near-infrared spectroscopy and magnetic resonance imaging monitoring of tumor response to combretastatin A-4-phosphate correlated with therapeutic outcome.

Authors:  Dawen Zhao; Cheng-Hui Chang; Jae G Kim; Hanli Liu; Ralph P Mason
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-02-23       Impact factor: 7.038

Review 4.  The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents.

Authors:  Dietmar W Siemann
Journal:  Cancer Treat Rev       Date:  2010-06-08       Impact factor: 12.111

5.  In vivo preclinical photoacoustic imaging of tumor vasculature development and therapy.

Authors:  Jan Laufer; Peter Johnson; Edward Zhang; Bradley Treeby; Ben Cox; Barbara Pedley; Paul Beard
Journal:  J Biomed Opt       Date:  2012-05       Impact factor: 3.170

Review 6.  Combretastatin A4 phosphate: a novel vascular disrupting agent.

Authors:  Govardhanan Nagaiah; Scot C Remick
Journal:  Future Oncol       Date:  2010-08       Impact factor: 3.404

7.  Comparative preclinical pharmacokinetic and metabolic studies of the combretastatin prodrugs combretastatin A4 phosphate and A1 phosphate.

Authors:  Ian G Kirwan; Paul M Loadman; David J Swaine; D Alan Anthoney; George R Pettit; John W Lippert; Steve D Shnyder; Patricia A Cooper; Mike C Bibby
Journal:  Clin Cancer Res       Date:  2004-02-15       Impact factor: 12.531

8.  In vivo measurement of vascular modulation in experimental tumors using a fluorescent contrast agent.

Authors:  Gianluca Valentini; Cosimo D'Andrea; Raffaele Ferrari; Antonio Pifferi; Rinaldo Cubeddu; Michele Martinelli; Claudia Natoli; Paolo Ubezio; Raffaella Giavazzi
Journal:  Photochem Photobiol       Date:  2008-04-12       Impact factor: 3.421

9.  Vascular effects dominate solid tumor response to treatment with combretastatin A-4-phosphate.

Authors:  Sarah Jane Lunt; Simon Akerman; Sally A Hill; Matthew Fisher; Victoria J Wright; Constantino C Reyes-Aldasoro; Gillian M Tozer; Chryso Kanthou
Journal:  Int J Cancer       Date:  2011-04-13       Impact factor: 7.396

10.  Noninvasive optical measurement of cerebral blood flow in mice using molecular dynamics analysis of indocyanine green.

Authors:  Taeyun Ku; Chulhee Choi
Journal:  PLoS One       Date:  2012-10-31       Impact factor: 3.240

View more
  6 in total

1.  Evaluation of tumor ischemia in response to an indole-based vascular disrupting agent using BLI and (19)F MRI.

Authors:  Heling Zhou; Rami R Hallac; Ramona Lopez; Rebecca Denney; Matthew T MacDonough; Li Li; Li Liu; Edward E Graves; Mary Lynn Trawick; Kevin G Pinney; Ralph P Mason
Journal:  Am J Nucl Med Mol Imaging       Date:  2015-01-15

2.  Design and Evaluation of Rhein-Based MRI Contrast Agents for Visualization of Tumor Necrosis Induced by Combretastatin A-4 Disodium Phosphate.

Authors:  Libang Zhang; Dongjian Zhang; Meng Gao; Qiaomei Jin; Cuihua Jiang; Tianze Wu; Yuanbo Feng; Yicheng Ni; Zhiqi Yin; Jian Zhang
Journal:  Mol Imaging Biol       Date:  2020-10-13       Impact factor: 3.488

3.  Dynamic bioluminescence and fluorescence imaging of the effects of the antivascular agent Combretastatin-A4P (CA4P) on brain tumor xenografts.

Authors:  Li Liu; Ralph P Mason; Barjor Gimi
Journal:  Cancer Lett       Date:  2014-10-08       Impact factor: 8.679

4.  Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.

Authors:  Bradley J Monk; Michael W Sill; Joan L Walker; Christopher J Darus; Gregory Sutton; Krishnansu S Tewari; Lainie P Martin; Jeanne M Schilder; Robert L Coleman; Jai Balkissoon; Carol Aghajanian
Journal:  J Clin Oncol       Date:  2016-05-23       Impact factor: 44.544

5.  The vascular disrupting agent combretastatin A-4 phosphate causes prolonged elevation of proteins involved in heme flux and function in resistant tumor cells.

Authors:  Sanchareeka Dey; Sharda Kumari; Sarada Preeta Kalainayakan; James Campbell; Poorva Ghosh; Heling Zhou; Keely E FitzGerald; Maoping Li; Ralph P Mason; Li Zhang; Li Liu
Journal:  Oncotarget       Date:  2017-12-28

6.  Power Doppler ultrasound and contrast-enhanced ultrasound demonstrate non-invasive tumour vascular response to anti-vascular therapy in canine cancer patients.

Authors:  Eline Abma; Emmelie Stock; Ward De Spiegelaere; Leen Van Brantegem; Katrien Vanderperren; Yicheng Ni; Matthijs Vynck; Sylvie Daminet; Kaat De Clercq; Hilde de Rooster
Journal:  Sci Rep       Date:  2019-06-25       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.